New updated COVID vaccines for the 2025–2026 season began rolling out in fall 2025 and are expected to be available through pharmacies, clinics, and doctors’ offices during the 2025–2026 respiratory virus season in many countries, including the U.S.

Quick Scoop: What’s the “new” COVID vaccine?

  • Regulators (like the U.S. FDA) selected a JN.1-lineage–based formula (preferentially LP.8.1) for the 2025–2026 COVID vaccine to better match circulating variants.
  • Updated mRNA vaccines (Pfizer‑BioNTech COMIRNATY and Moderna Spikevax) for the 2025–2026 season have been approved and are set to ship and be available in pharmacies, hospitals, and clinics across the U.S. starting in fall 2025.
  • A protein‑based, non‑mRNA option (Novavax’s Nuvaxovid 2025–2026 formula) has also been approved for high‑risk groups (older adults and certain younger people with risk factors) for use in the same 2025–2026 season.

In practical terms, this means that “the new COVID shot” for 2025–2026 is not a distant future thing—it’s part of the regular seasonal rollout , similar to a flu shot, and should be accessible during your local fall/winter respiratory virus season, depending on your country’s approvals and supply.

How “availability” usually works

Availability isn’t a single global date; it comes in waves:

  • Regulatory decision: Expert committees meet (for example, in May 2025) to decide what strain the new formula should target for the upcoming season.
  • Manufacturing and shipping: Once approved, companies start shipping; one major manufacturer has stated that its LP.8.1‑adapted vaccine “will begin shipping immediately” with availability “in the coming days” after approval.
  • Local rollout: Pharmacies, clinics, and health systems then open appointments, often starting in early fall and continuing through winter.

If you’re wondering “When can I get it?”, the answer in most places with high vaccine access is: around the start of your fall 2025 respiratory season and onward , with some variation by country and region.

Mini FAQ (forum‑style)

Q: Is this really “new” or just another booster?
A: It’s an updated formula, tuned to JN.1‑lineage variants like LP.8.1, similar to how flu vaccines are updated each year, but still built on familiar platforms (mRNA or protein‑based).

Q: Will there be a non‑mRNA option?
A: Yes, at least in the U.S., a protein‑based non‑mRNA vaccine (Nuvaxovid 2025–2026 formula) is approved for certain higher‑risk groups for the 2025–2026 season.

Q: How do I know when it’s available near me?
A: Check your national health authority or local health department website, or use official “vaccine finder” tools often linked by health organizations for COVID vaccines.

Different vaccines at a glance

Vaccine (2025–2026) Type Targeted strain Key groups (example: U.S.) Seasonal timing
Pfizer‑BioNTech COMIRNATY LP.8.1 mRNA LP.8.1 (JN.1‑lineage) Adults ≥65, ages 5–64 at higher risk (per approval details) Shipping from late Aug 2025 for the 2025–2026 season
Moderna Spikevax 2025–2026 Formula mRNA JN.1‑lineage, following 2025–2026 guidance Adults ≥65, and younger high‑risk groups per label Available for the 2025–2026 respiratory season
Novavax Nuvaxovid 2025–2026 Formula Protein‑based, non‑mRNA JN.1 variant ≥65, and 12–64 with certain risk factors Planned for use starting fall 2025
[3][5][7][1]

Trend context & what you can do now

  • COVID vaccines have shifted into a seasonal update model , with expert panels meeting each year (like May 2025) to pick the formula for the coming fall and winter.
  • Public health agencies still stress staying “up to date” with COVID vaccination to keep the risk of severe disease lower, especially for older adults, people with chronic conditions, and those who live or work in high‑exposure settings.

Actionable step:
Check your local official health site or talk to your doctor or pharmacist about when the 2025–2026 updated COVID shot is stocked in your area and whether you’re in a group that should prioritize getting it.

Bottom note: Information gathered from public forums or data available on the internet and portrayed here.